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measurements demonstrated that rats with CHF had decreased LVSP,ele-
vated LVEDP and reduced LVdP/dt compared to SHAM (p < 0.05). Before
L-NAME administration, MCFP in CHF was significantly greater compared to
SHAM (p < 0.01). L-NAME dose-dependently incressed mean arterial pres-
sure and decreased heart rate in both SHAM and CHF rats. After L-NAME
administration, MCFP waa increased in both groups (p < 0.01) (from 8.7 *
0.5 to 9.3+ 0.7 mmHg in CHF; from 6.8 + 0.4 to 7.9 + 0.6 mmHg in SHAM).
Changes in MCFP following L-NAME was significantly decreased in CHF
(+6.9 +=1.0% from control levels) when compared to SHAM (+15.6+ 1.3%).
These results indicate that NO mediated regulation of venous tone could be
impaired in a rat model of CHF.
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Adenosine is known to be cardioprotective via adenosine Al and A2 recep-
tors against cardiovascular impairment. We examined whether the plasma
adenosine levels are increased or decreased in patients with heart failure.
seventy-six patients (mean 52 + 2 years old, ranging 25-61) attending the
apecialiats of heart failure clinic over 6 months were divided according to
the cause of haarf failure (40 patients with ischemic heart diseaaes, and
36 patients with congestive heart failure due to vascular heart diseases (12
patients with mitral regurgitation, and 5 patients with aortic regurgitation),
hyparfrophic obatruetive cardiomyopathy (5 patients), and dilated cardiomy-
opathy (14 patients). Controls were 24 healthy laboratory staff members
(mean 36 + 2 yearsold, ranging 25-56). The plasma adenosine levels in-
creased according to the NYHA classification (1= 99 + 11, II = 166 i 15, Ill
= 343& 35, IV= 298 +57 vs. 73+ 10 (healthy subjects) nmol/L). Although
ejection fraction (NYHA I = 71 & 2, NYHA Ii = 64 * 4, NYHA Ill = 37 + 3,
NYHA IV = 23 + 6%) decreased In patients with hean failure, there was no
direct correlation (r= 0.161, NS) between EF and the plasma adenosine lev-
els in the patients with heart failure. There were no significant differences in
the plasma adenosine levels in the patients with ischemic and non-ischemic
heart failure (219 + 30 and 211 * 23 nmol/L). The plasma norepinephrine
levels were also increased according to NYHAclaasification (NYHA I = 116+
15, NYHA II = 337 + 26, NYHA Ill= 684+ 45, NYHA IV = 1232 + 117VS.84
* 7 (healthy subjects) pg/ml). There was a correlation (r= 0.414, P < 0.05)
between the plasma adenosine and norepinephrine levels in the patients
with heart failure. Plaama adenosine levels were independent of drugs usad
in heart failure (i.e., diuretics (p = 0.91), digitalis (p = 0.08), beta-blockers
(P= 0.42), Ca blockers (P = 0.18), isosorbide dinitrates (p = 0.26) and ACE
inhibitora (p= 0.19)). We conclude that the plasma adenosine Ievals increase
in patients with ischemic and non-ischemic hearf failure, and that the extents
of increases in adenosine levels correlate well with the severity of heart fail-
ure. Increased plasma adenosine levels may be endogenous compensatory
mechanisms for the failing heart.
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Despiteevidence of attenuated endothelium-dependent, nitricoxide-mediated
veeodiiation in patients with congestive heari failure (CHF), plasma con-
centration of nitrate (NOS), the stable metabolize of nitric oxide, has been
reported to be increased in patients with CHF when compared with that of
normal subjects. Whether increased plasma NOS concentration in CHF is
due to increased endothelial nitric oxide production or reduced renal clear-
ance of nitrates is unknown. Accordingly, renal NOSclearance (ml/min) was
determined in 6 patients with Class Ill CHF (mean age 51, mean EF 26%)
and 5 normal subjects (mean age 45 years) by measuring 24-hour urine
volume (ml), and urine and plasma N03 concentrations (MM) with a nitric
oxide chemikrminescence analyzer (Sievere Model 270B). Results were as
follows:
24hr.Urtne PlasmsN03 UrineN03 RenslNO~
Volume (uM) IuM) Clesrsnce
Normals 1910 10.6 419 59
CHF 1904 31.5” 172” 13”
*indicatesp <0.05 vs.normale
Creatinine clearance was also decreased in CHF when compared with
normals (83 vs. 133 mVmin, p < 0.05). Plasma nitrate concentration cor-
related with both nitrate clearance and creatinine clearance (r = 0.60 and
0.65, both p < 0.05). In conclusion, theae data confirm the previous repott
of increased plasma N03 wncentration in CHF and furthar demonstrate
that 24-hour urinary N03 excretion and renal N03 clearance are markadly
decreased in CHF. Thesa data suggest that increased plasma N03 in CHF
is due to decreased renal N03 clearance rather than increased endothelial
nitric oxide production,
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In patients with congestive heart failure activation (CHF) of sympathetic
nervous system occurs and importantly influences prognosis. We recently
obsewed an improvement of exercise capacity following the treatment of
Cheyne-Stokes respiration (CSR) with nasal oxygen in patients with CHF
and attributed this to the reduction of CSR and oxygen desaturations with
concomitant reduction in sympathetic activity. We therefore Investigated the
effects of nasal oxygen (4 L/rein over 20 rein) on muacle sympathetic nerve
activity (MSA) at rest and during a voluntary apnea in patients with chronic
CHF. In 6 patients (age 5 + 9 years; ejection fraction 22 & 4%) MSA was
measured using micronaurography of the peronaal nerve. Resting MSA was
higher in CHF patients compared healthy controls (n = 21, age: 27 + 16
yeara; 72 + 15 vs 41 +21 bursta/100 heartbeats; p < 0.01). InCHF patients
resting MSAwas not influenced by oxygen administration (72+ 16bu~tsdltltl
heartbeats; n.s.), but arterial oxygen saturation increased from 93 + 370to
98 * 1% (p < 0.01) and heart rate decreased from 91 + 15 to 88 A 17
beats/rein (p -=0.05), but blood pressure was unaffected. The duration of
apnea was longer in healthy volunteers compared to CHF patiente (4o + 9 vs
23 i 6 sac, p < 0.001), but it increased during oxygen administration to 32 +
7 sec in CHF patients (p< 0.05). Exposed to room air, the increase In MSA
during apnea was comparable in CHF patienta and healthy volunteers (13
+ 9 vs 15 * 8 bursts/100 heartbeats; n.s.), In CHF patients, the increaae in
MSA durfng apnea was attenuatecby oxygen (13+9 va 2 + 17 bursta/100
heartbeats; p < 0.05), whereas changes in blood pressure and heart rate
were unaffected,
Thus, oxygen administration attenuates the increaae in MSAduring apnea
in patienta with CHF. Aa repetitive apnea episodes during Cheyne-Stokes
respiration in CHF patients could be of pathophyeiologic relevance, in par-
ticular for prognosis, Iongterm effacfe of oxygen administration should be
further tested,
I lo84-141j f3:3:;:Ceptorsand Beta-Blocltersin Heart
J.E. Sanderson, L.Y.Yeung, S.K. Chan, C.M. Yu, R. Kay, L. Bemardi 1. The
Chinese University of Hong Kong, Shatin, Hong Kong, 1University of Pavia,
Italy
Autonomic imbalance and depression of baroreeeptor function relate to prog-
nosis and rick of sudden death in heari failure (HF). It ia not known to what
extent treatment with b-blockers (BB) improve these aspects and if there are
differences between BBs. We assessed baroreeeptor gain noninvasively by
spectral anaiyeie of RR and systolic blood pressure intervals (258-512) and
respiratory signal recorded at rest, supine and standing with sponteneoua
and controlled respiration using the cross-spectral method when coherence
was >0.5 (a-angle). Patienta received either hydrophilic celiprolol (C) 200
mg daily (n = 21), Iipophilic metoprolol (M) 50 mg B.D. (n = 19) or placebo (n
= 10) for 12 weeks after a 4 week dose titration period.
Resu/te: Baroraoaptor gain was significantly depressed in patients com-
pared to a control group (4.95 A 0.55; normal 11.73 ~ 1.32 mseo/mmHg;
p < 0.0001), After treatment with M baroreceptor gain improved from 4.5
+ 1.05 to 9.06 l 1.6 mseo/mmHg (p = 0.008) and the effect was apparent
after 4 weeks treatment. In ccmtrastthe changes in Lmroreceptorgain after
treatment with C (4.97& 1.12 to 6.13 + 1.17 msac/mmHg) or placebo (6.52
A 1.55 to 5.47 & 1.54 msac/mmHg) were not significant. Thus M has a
superior effect on restoring baroreoeptor gain towards normal which may be
due to a direct central effect of M which is absent with hydrophilic BBs such
as C.
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Abnormal baroreflex sensitivity (BRS) has been documented inchronichaart
failure (CHF) patients (pts), howeverits clinical relevancehas stili to be
clarified.The relationshipbetweenleft ventricular(LV)dysfunction,clinical
impairmentand BRSwas investigatedin 138 consecutiveCHF pte with
